INTRODUCTION: Hydroxymethylglutaryl-coenzyme A inhibitors (statins) are used in hyperlipidemia (HL) treatment and are the most efficacious and widely used drug, especially in decreasing low-density lipoprotein cholesterol, have been found to reduce mortality and morbidity in coronary artery disease in a great number of studies. However, the development of depression in patients under statin treatment has been evaluated in very few studies. Thus, this study aims to evaluate the influence of therapy by statin and statin derivatives on anxiety and depression.
METHODS: This study was a prospective observational study included in patients who were started on statin HL treatment. The patients were found to be administered atorvastatin (10 mg) or rosuvastatin (10 mg) for HL treatment. Those patients were followed up for 10 months. Pre- and post-treatment status of anxiety and depression of the patients was evaluated using the hospital anxiety and depression scale.
RESULTS: This study was performed on a total of 219 patients who were diagnosed to have HL. Moreover, 194 (88.5%) and 25 (11.5%) patients were administered atorvastatin and rosuvastatin, respectively. The anxiety score was found 9.0 (5.012.0) before the treatment and 8.0 (5.012.0) after the treatment (p=0.062). In addition, the depression score was found 5.0 (3.09.0) before and 5.0 (3.09.0) after the treatment (p=0.078).
DISCUSSION AND CONCLUSION: Statins are among the most frequently used drug groups for long-term HL treatment. However, this study did not find any significant association between statin therapy and depression or anxiety scores.